No Data
No Data
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $332
RBC Capital analyst Gregory Renza maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $328 to $332.According to TipRanks data, the analyst has a success rate of 45.4% and a
Amgen's Dezmaab injection has been approved for a new indication in China.
DiShuSingle Antibody Injection has been approved for three indications in China.
FDA Grants Expanded Approval for Amgen's Blincyto in ALL
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type With Blincyto
By Sabela Ojea Amgen said the Food and Drug Administration has approved Blincyto to treat an aggressive type of blood cancer. The biotechnology company on Friday said the approval is aimed at adult
Express News | Amgen Announces FDA Approval Of BLINCYTO In CD19-Positive Philadelphia Chromosome-Negative B-ALL
Express News | Amgen- Blincyto Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Vs Chemotherapy Alone
No Data